FDA Clears Potential IPF Therapy, IM156, for Phase 1 Trial
The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ImmunoMet Therapeutics‘ treatment candidate for idiopathic pulmonary fibrosis (IPF), IM156. The decision grants ImmunoMet permission to open studies of the therapy in people in the U.S. “FDA clearance of an IND for…